3,6-bis(2-piperidinoethoxy)acridine trihydrochloride: immunomodulator; structure given in first source; RN given for tri-HCl [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 133712 |
| CHEMBL ID | 576799 |
| SCHEMBL ID | 9827046 |
| MeSH ID | M0132437 |
| Synonym |
|---|
| 3,6-bis[2-(1-piperidyl)ethoxy]acridine |
| 3,6-bis(2-piperidinoethoxy)acridine trihydrochloride |
| acridine, 3,6-bis[2-(1-piperidinyl)ethoxy]- |
| 81541-32-4 |
| 3,6-bis(2-piperidinoethoxy)acridine |
| cl 246,738 |
| gnf-pf-1482 , |
| CHEMBL576799 |
| 3,6-bis(2-piperidin-1-ylethoxy)acridine |
| unii-ip2pou1mkn |
| acridine, 3,6-bis(2-(1-piperidinyl)ethoxy)- |
| ip2pou1mkn , |
| cl-246738 free base |
| SCHEMBL9827046 |
| DTXSID40231194 |
| QKPASNYRBWHSBK-UHFFFAOYSA-N |
| cl-246738 |
| 3,6-bis(2-piperidinoethoxy) acridine |
| 3,6-bis(2-(1-piperidinyl)ethoxy)acridine |
| cl-2l |
| 3,6-bis(2-(piperidin-1-yl)ethoxy)acridine |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Toxic effects of the drug at high doses included nausea, diarrhoea and decreased levels of consciousness." | ( A phase I study of immunostimulation and toxicity in patients with colorectal carcinoma using the immunomodulator 3,6-bis(2-piperidinoethoxy) acridine trihydrochloride (CL 246738). Dickinson, A; Halcrow, P; Hales, J; Harris, AL; Lawrence, GF; Lennard, TW; McDonald, M; Shenton, BK; Taylor, RM; Wolstencroft, R, 1989) | 0.28 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The orally bioavailable lead imidazolopiperazine confers complete causal prophylactic protection (15 milligrams/kilogram) in rodent models of malaria and shows potent in vivo blood-stage therapeutic activity." | ( Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. Barnes, SW; Bonamy, GM; Bopp, SE; Borboa, R; Bright, AT; Chatterjee, A; Che, J; Cohen, S; Dharia, NV; Diagana, TT; Fidock, DA; Froissard, P; Gagaring, K; Gettayacamin, M; Glynne, RJ; Gordon, P; Groessl, T; Kato, N; Kuhen, KL; Lee, MC; Mazier, D; McNamara, CW; Meister, S; Nagle, A; Nam, TG; Plouffe, DM; Richmond, W; Roland, J; Rottmann, M; Sattabongkot, J; Schultz, PG; Tuntland, T; Walker, JR; Winzeler, EA; Wu, T; Zhou, B; Zhou, Y, 2011) | 0.37 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID449704 | NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay | 2008 | Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26 | In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. |
| AID449703 | NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay | 2008 | Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26 | In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. |
| AID449706 | NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested. | 2008 | Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26 | In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. |
| AID449705 | NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7) | 2008 | Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26 | In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. |
| AID602156 | Novartis GNF Liver Stage Dataset: Malariabox Annotation | 2011 | Science (New York, N.Y.), Dec-09, Volume: 334, Issue:6061 | Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 8 (47.06) | 18.7374 |
| 1990's | 7 (41.18) | 18.2507 |
| 2000's | 1 (5.88) | 29.6817 |
| 2010's | 1 (5.88) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 18 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Substance | Relationship Strength | Studies | Trials | Classes | Roles |
|---|---|---|---|---|---|
| quinacrine Quinacrine: An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.. quinacrine : A member of the class of acridines that is acridine substituted by a chloro group at position 6, a methoxy group at position 2 and a [5-(diethylamino)pentan-2-yl]nitrilo group at position 9. | 2.46 | 2 | 0 | acridines; aromatic ether; organochlorine compound; tertiary amino compound | antimalarial; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor |
| alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid: An IBOTENIC ACID homolog and glutamate agonist. The compound is the defining agonist for the AMPA subtype of glutamate receptors (RECEPTORS, AMPA). It has been used as a radionuclide imaging agent but is more commonly used as an experimental tool in cell biological studies. | 2.06 | 1 | 0 | non-proteinogenic alpha-amino acid | |
| 1,3-dipropyl-8-cyclopentylxanthine DPCPX : An oxopurine that is 7H-xanthine substituted at positions 1 and 3 by propyl groups and at position 8 by a cyclohexyl group. | 2.46 | 2 | 0 | oxopurine | adenosine A1 receptor antagonist; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor |
| nsc-267703 [no description available] | 2.06 | 1 | 0 | anthracycline | |
| dactinomycin [no description available] | 2.06 | 1 | 0 | cyclodepsipeptide | |
| 1-aminoindan-1,5-dicarboxylic acid 1-aminoindan-1,5-dicarboxylic acid: structure given in first source | 2.46 | 2 | 0 | ||
| amodiaquine Amodiaquine: A 4-aminoquinoline compound with anti-inflammatory properties.. amodiaquine : A quinoline having a chloro group at the 7-position and an aryl amino group at the 4-position. | 2.06 | 1 | 0 | aminoquinoline; organochlorine compound; phenols; secondary amino compound; tertiary amino compound | anticoronaviral agent; antimalarial; drug allergen; EC 2.1.1.8 (histamine N-methyltransferase) inhibitor; non-steroidal anti-inflammatory drug; prodrug |
| astemizole Astemizole: Antihistamine drug now withdrawn from the market in many countries because of rare but potentially fatal side effects.. astemizole : A piperidine compound having a 2-(4-methoxyphenyl)ethyl group at the 1-position and an N-[(4-fluorobenzyl)benzimidazol-2-yl]amino group at the 4-position. | 2.46 | 2 | 0 | benzimidazoles; piperidines | anti-allergic agent; anticoronaviral agent; H1-receptor antagonist |
| berberine [no description available] | 2.06 | 1 | 0 | alkaloid antibiotic; berberine alkaloid; botanical anti-fungal agent; organic heteropentacyclic compound | antilipemic drug; antineoplastic agent; antioxidant; EC 1.1.1.141 [15-hydroxyprostaglandin dehydrogenase (NAD(+))] inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.13.11.52 (indoleamine 2,3-dioxygenase) inhibitor; EC 1.21.3.3 (reticuline oxidase) inhibitor; EC 2.1.1.116 [3'-hydroxy-N-methyl-(S)-coclaurine 4'-O-methyltransferase] inhibitor; EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor; EC 2.7.11.10 (IkappaB kinase) inhibitor; EC 3.1.1.4 (phospholipase A2) inhibitor; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor; EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; geroprotector; hypoglycemic agent; metabolite; potassium channel blocker |
| chloroquine Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis. | 2.46 | 2 | 0 | aminoquinoline; organochlorine compound; secondary amino compound; tertiary amino compound | anticoronaviral agent; antimalarial; antirheumatic drug; autophagy inhibitor; dermatologic drug |
| aricine [no description available] | 2.46 | 2 | 0 | cinchona alkaloid | |
| clofilium clofilium: RN given refers to parent cpd; structure | 2.06 | 1 | 0 | benzenes; organic amino compound | |
| clotrimazole [no description available] | 2.46 | 2 | 0 | conazole antifungal drug; imidazole antifungal drug; imidazoles; monochlorobenzenes | antiinfective agent; environmental contaminant; xenobiotic |
| dequalinium Dequalinium: A topical bacteriostat that is available as various salts. It is used in wound dressings and mouth infections and may also have antifungal action, but may cause skin ulceration.. dequalinium : A quinolinium ion comprising decane in which one methyl hydrogen at each end of the molecule has been replaced by a 4-amino-2-methylquinolin-1-yl group. | 2.06 | 1 | 0 | quinolinium ion | antifungal agent; antineoplastic agent; antiseptic drug; mitochondrial NADH:ubiquinone reductase inhibitor |
| nsc-526417 [no description available] | 2.06 | 1 | 0 | ||
| gentian violet crystal violet cation : An iminium ion that is malachite green cation in which the hydrogen at the para- psition of the monosubstituted phenyl group is replaced by a dimethylamino group. | 2.06 | 1 | 0 | iminium ion | antibacterial agent; antifungal agent |
| hexahydrosiladifenidol [no description available] | 2.06 | 1 | 0 | ||
| mefloquine hydrochloride [2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol : An organofluorine compound that consists of quinoline bearing trifluoromethyl substituents at positions 2 and 8 as well as a (2-piperidinyl)hydroxymethyl substituent at position 4. | 2.46 | 2 | 0 | organofluorine compound; piperidines; quinolines; secondary alcohol | |
| moclobemide Moclobemide: A reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties.. moclobemide : A member of the class of benzamides that is benzamide substituted by a chloro group at position 4 and a 2-(morpholin-4-yl)ethyl group at the nitrogen atom. It acts as a reversible monoamine oxidase inhibitor and is used in the treatment of depression. | 2.46 | 2 | 0 | benzamides; monochlorobenzenes; morpholines | antidepressant; environmental contaminant; xenobiotic |
| n-acetyl-4-nitrophenylserinol N-acetyl-4-nitrophenylserinol: RN given refers to cpd without isomeric designation; structure | 2.46 | 2 | 0 | ||
| oxiracetam oxiracetam: structure in first source | 2.46 | 2 | 0 | organonitrogen compound; organooxygen compound | |
| pentamidine Pentamidine: Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.. pentamidine : A diether consisting of pentane-1,5-diol in which both hydroxyl hydrogens have been replaced by 4-amidinophenyl groups. A trypanocidal drug that is used for treatment of cutaneous leishmaniasis and Chagas disease. | 2.46 | 2 | 0 | aromatic ether; carboxamidine; diether | anti-inflammatory agent; antifungal agent; calmodulin antagonist; chemokine receptor 5 antagonist; EC 2.3.1.48 (histone acetyltransferase) inhibitor; NMDA receptor antagonist; S100 calcium-binding protein B inhibitor; trypanocidal drug; xenobiotic |
| pronethalol pronethalol: was heading 1964-94 (Prov 1964-66); NAPHTHYLISOPROTERENOL was see PRONETHALOL 1977-94; use ETHANOLAMINES to search PRONETHALOL 1966-94 | 2.46 | 2 | 0 | naphthalenes | |
| propafenone Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.. propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias. | 2.46 | 2 | 0 | aromatic ketone; secondary alcohol; secondary amino compound | anti-arrhythmia drug |
| pyrimethamine Maloprim: contains above 2 cpds | 2.46 | 2 | 0 | aminopyrimidine; monochlorobenzenes | antimalarial; antiprotozoal drug; EC 1.5.1.3 (dihydrofolate reductase) inhibitor |
| scriptaid scriptide: provokes translocation of GLUT4 to increase glucose uptake; structure in first source | 2.46 | 2 | 0 | isoquinolines | |
| tilorone Tilorone: An antiviral agent used as its hydrochloride. It is the first recognized synthetic, low-molecular-weight compound that is an orally active interferon inducer, and is also reported to have antineoplastic and anti-inflammatory actions.. tilorone : A member of the class of fluoren-9-ones that is 9H-fluoren-9-one which is substituted by a 2-(diethylamino)ethoxy group at positions 2 and 7. It is an interferon inducer and a selective alpha7 nicotinic acetylcholine receptor (alpha7 nAChR) agonist. Its hydrochloride salt is used as an antiviral drug. | 2.67 | 3 | 0 | aromatic ether; diether; fluoren-9-ones; tertiary amino compound | anti-inflammatory agent; antineoplastic agent; antiviral agent; interferon inducer; nicotinic acetylcholine receptor agonist |
| 6,18,30-trimethyl-3,9,12,15,21,24,27,33,36-nona(propan-2-yl)-1,7,13,19,25,31-hexaoxa-4,10,16,22,28,34-hexazacyclohexatriacontane-2,5,8,11,14,17,20,23,26,29,32,35-dodecone [no description available] | 2.46 | 2 | 0 | cyclodepsipeptide | |
| cycloheximide Cycloheximide: Antibiotic substance isolated from streptomycin-producing strains of Streptomyces griseus. It acts by inhibiting elongation during protein synthesis.. cycloheximide : A dicarboximide that is 4-(2-hydroxyethyl)piperidine-2,6-dione in which one of the hydrogens attached to the carbon bearing the hydroxy group is replaced by a 3,5-dimethyl-2-oxocyclohexyl group. It is an antibiotic produced by the bacterium Streptomyces griseus. | 2.46 | 2 | 0 | antibiotic fungicide; cyclic ketone; dicarboximide; piperidine antibiotic; piperidones; secondary alcohol | anticoronaviral agent; bacterial metabolite; ferroptosis inhibitor; neuroprotective agent; protein synthesis inhibitor |
| phanquinone phanquinone: structure. phanquone : An orthoquinone that is the 5,6-diketo derivative of 4,7-phenanthroline. | 2.46 | 2 | 0 | orthoquinones | |
| diphenan [no description available] | 2.46 | 2 | 0 | diarylmethane | |
| 2-phenylacetamide 2-phenylacetamide: structure. 2-phenylacetamide : A monocarboxylic acid amide that is acetamide substituted by a phenyl group at position 2. | 2.46 | 2 | 0 | monocarboxylic acid amide | mouse metabolite |
| tetraphenylborate Tetraphenylborate: An anionic compound that is used as a reagent for determination of potassium, ammonium, rubidium, and cesium ions. It also uncouples oxidative phosphorylation and forms complexes with biological materials, and is used in biological assays. | 2.46 | 2 | 0 | ||
| cycloguanil hydrochloride cycloguanil hydrochloride : The hydrochloride salt of cycloguanil. | 2.46 | 2 | 0 | hydrochloride; organic molecular entity | |
| cycloguanil cycloguanil: the active metabolite of proguanil; antifolate drug; structure in first source. cycloguanil : A triazine in which a 1,6-dihydro-1,3,5-triazine ring is substituted at N-1 by a 4-chlorophenyl group, at C-2 and -4 by amino groups and at C-6 by gem-dimethyl groups. A dihydrofolate reductase inhibitor, it is a metabolite of the antimalarial drug proguanil. | 2.06 | 1 | 0 | triazines | antifolate; antiinfective agent; antimalarial; antiparasitic agent; antiprotozoal drug; EC 1.5.1.3 (dihydrofolate reductase) inhibitor |
| acridines Acridines: Compounds that include the structure of acridine.. acridine : A polycyclic heteroarene that is anthracene in which one of the central CH groups is replaced by a nitrogen atom. | 4.05 | 15 | 0 | acridines; mancude organic heterotricyclic parent; polycyclic heteroarene | genotoxin |
| triphenyltetrazolium triphenyltetrazolium: RN given refers to parent cpd. 2,3,5-triphenyltetrazolium : An organic cation that is tetrazole carrying three phenyl substituents at positions 2, 3 and 5. | 2.06 | 1 | 0 | organic cation | |
| berbamine [no description available] | 2.06 | 1 | 0 | phenylpropanoid | |
| emetine Emetine: The principal alkaloid of ipecac, from the ground roots of Uragoga (or Cephaelis) ipecacuanha or U. acuminata, of the Rubiaceae. It is used as an amebicide in many different preparations and may cause serious cardiac, hepatic, or renal damage and violent diarrhea and vomiting. Emetine inhibits protein synthesis in EUKARYOTIC CELLS but not PROKARYOTIC CELLS.. emetine : A pyridoisoquinoline comprising emetam having methoxy substituents at the 6'-, 7'-, 10- and 11-positions. It is an antiprotozoal agent and emetic. It inhibits SARS-CoV2, Zika and Ebola virus replication and displays antimalarial, antineoplastic and antiamoebic properties. | 2.46 | 2 | 0 | isoquinoline alkaloid; pyridoisoquinoline | antiamoebic agent; anticoronaviral agent; antiinfective agent; antimalarial; antineoplastic agent; antiprotozoal drug; antiviral agent; autophagy inhibitor; emetic; expectorant; plant metabolite; protein synthesis inhibitor |
| dequalinium chloride dequalinium chloride : An organic chloride salt that is the dichloride salt of dequalinium. | 2.46 | 2 | 0 | organic chloride salt | antifungal agent; antineoplastic agent; antiseptic drug; mitochondrial NADH:ubiquinone reductase inhibitor |
| gentian violet Gentian Violet: A dye that is a mixture of violet rosanilinis with antibacterial, antifungal, and anthelmintic properties.. crystal violet : An organic chloride salt that is the monochloride salt of crystal violet cation. It has been used in creams for the topical treatment of bacterial and fungal infections, being effective against some Gram-positive bacteria (notably Staphylococcus species) and some pathogenic fungi (including Candida species) but use declined following reports of animal carcinogenicity. It has also been used for dying wood, silk, and paper, as well as a histological stain. | 2.04 | 1 | 0 | organic chloride salt | anthelminthic drug; antibacterial agent; antifungal agent; antiseptic drug; histological dye |
| Berberine chloride (TN) [no description available] | 2.46 | 2 | 0 | organic molecular entity | |
| 9,10-dimethylanthracene 9,10-dimethylanthracene: RN given refers to parent ion | 2.46 | 2 | 0 | ||
| c 137 C 137: RN given refers to parent cpd | 2.46 | 2 | 0 | ||
| palmatine burasaine: structure in first source | 2.06 | 1 | 0 | berberine alkaloid; organic heterotetracyclic compound | plant metabolite |
| 4,6-diamino-2,2-dimethyl-1,2-dihydro-1-phenyl-s-triazine 4,6-diamino-2,2-dimethyl-1,2-dihydro-1-phenyl-s-triazine: structure in first source | 2.06 | 1 | 0 | ||
| buquinolate [no description available] | 2.46 | 2 | 0 | ||
| zidovudine Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase. | 1.99 | 1 | 0 | azide; pyrimidine 2',3'-dideoxyribonucleoside | antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor |
| propranolol glycol propranolol glycol: propranolol metabolite; potent anticonvulsant against strychnine induced convulsions | 2.46 | 2 | 0 | ||
| ribavirin Rebetron: Rebetron is tradename | 1.97 | 1 | 0 | 1-ribosyltriazole; aromatic amide; monocarboxylic acid amide; primary carboxamide | anticoronaviral agent; antiinfective agent; antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor |
| naphthoxybutanolcyclohexylamine naphthoxybutanolcyclohexylamine: structure | 2.06 | 1 | 0 | ||
| staurosporine [no description available] | 2.06 | 1 | 0 | indolocarbazole alkaloid; organic heterooctacyclic compound | apoptosis inducer; bacterial metabolite; EC 2.7.11.13 (protein kinase C) inhibitor; geroprotector |
| propamidine propamidine: structure given in first source. propamidine : A polyether that is the bis(4-guanidinophenyl) ether of propane-1,3-diol. Used (as its isethionate salt) for the treatment of minor eye or eyelid infections, such as conjunctivitis and blepharitis. | 2.06 | 1 | 0 | aromatic ether; guanidines; polyether | antimicrobial agent; antiseptic drug |
| thionine thionine: do not confuse with the thionins which is a class of polypeptides; RN above is for the chloride;. thionine : An organic chloride salt composed of 3,7-diaminophenothiazin-5-ium and chloride ions in a 1:1 ratio. A strongly metachromatic dye, useful for the staining of acid mucopolysaccharides. It is also a common nuclear stain and can be used for the demonstration of Nissl substance in nerve cells of the CNS. | 2.04 | 1 | 0 | ||
| neocuproine neocuproine: Spectrophotometric determination of copper and ultramicro blood sugar determinations; structure; RN given refers to parent cpd. neocuproine : A member of the class of phenanthrolines that is 1,10-phenanthroline bearing two methyl substituents at positions 2 and 9. | 2.46 | 2 | 0 | phenanthrolines | chelator; copper chelator |
| mefloquine hydrochloride [no description available] | 2.04 | 1 | 0 | hydrochloride | |
| toxoflavin toxoflavin: azapteridine antibiotic; structure. toxoflavin : A pyrimidotriazine that is 1,6-dimethyl-1,5,6,7-tetrahydropyrimido[5,4-e][1,2,4]triazine with oxo groups at positions 5 and 7. | 2.46 | 2 | 0 | carbonyl compound; pyrimidotriazine | antibacterial agent; antineoplastic agent; apoptosis inducer; bacterial metabolite; toxin; virulence factor; Wnt signalling inhibitor |
| selfotel selfotel: a N-methyl-D-aspartate (NMDA) antagonist; used to treat stroke-induced impairment | 2.04 | 1 | 0 | non-proteinogenic alpha-amino acid | |
| plasmenylserine plasmenylserine: RN given refers to (L)-isomer. O-phospho-L-serine : The L-enantiomer of O-phosphoserine.. O-phosphoserine : A serine derivative that is serine substituted at the oxygen atom by a phosphono group. | 2.46 | 2 | 0 | O-phosphoserine | EC 1.4.7.1 [glutamate synthase (ferredoxin)] inhibitor; EC 2.5.1.49 (O-acetylhomoserine aminocarboxypropyltransferase) inhibitor; EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite |
| quinocide quinocide: Russian drug; RN given refers to parent cpd; structure | 2.06 | 1 | 0 | ||
| 2,2',2''-terpyridine 2,2',2''-terpyridine: RN given refers to parent cpd. 2,2':6',2''-terpyridine : A tridentate heterocyclic ligand that binds metals at three meridional sites giving two adjacent 5-membered MN2C2 chelate rings. | 2.46 | 2 | 0 | terpyridines | chelator |
| clobetasone butyrate [no description available] | 2.06 | 1 | 0 | organic molecular entity | |
| cletoquine [no description available] | 2.46 | 2 | 0 | ||
| jatrorrhizine jatrorrhizine: isolated from bark of Enantia chlorantha (Annonaceae); structure given in first source | 2.06 | 1 | 0 | alkaloid | |
| lycorine lycorine: from bulbs of LYCORIS & other plants; RN given refers to (1 alpha,2 beta)-isomer; structure in Merck Index, 9th ed, #5444. lycorine : An indolizidine alkaloid that is 3,12-didehydrogalanthan substituted by hydroxy groups at positions and 2 and a methylenedioxy group across positions 9 and 10. Isolated from Crinum asiaticum, it has been shown to exhibit antimalarial activity. | 2.46 | 2 | 0 | indolizidine alkaloid | anticoronaviral agent; antimalarial; plant metabolite; protein synthesis inhibitor |
| bathophenanthroline 4,7-diphenyl-1,10-phenanthroline : A member of the class of phenanthrolines that is 1,10-phenanthroline bearing two phenyl substituents at positions 4 and 7. | 2.46 | 2 | 0 | benzenes; phenanthrolines | chelator |
| fascaplysine fascaplysine: from tropic sea sponges | 2.04 | 1 | 0 | ||
| LSM-4272 [no description available] | 2.06 | 1 | 0 | beta-carbolines | |
| tryptanthrine tryptanthrine: minor constituent of traditional Chinese medicine qing dai | 2.46 | 2 | 0 | alkaloid antibiotic; organic heterotetracyclic compound; organonitrogen heterocyclic compound | |
| ethylhydrocupreine ethylhydrocupreine: structure; RN given refers to parent cpd. optochin : A cinchona alkaloid consisting of 10,11-dihydrocinchonan bearing hydroxy and ethoxy substituents at positions 9 and 6' respectively. | 2.46 | 2 | 0 | aromatic ether; cinchona alkaloid | EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor |
| 2,4-diamino-5,6-dihydro-6,6-dimethyl-5-(4'-methoxyphenyl)-s-triazine 2,4-diamino-5,6-dihydro-6,6-dimethyl-5-(4'-methoxyphenyl)-s-triazine: RN given refers to parent cpd; structure given in first source | 2.06 | 1 | 0 | ||
| cinchonine [no description available] | 2.46 | 2 | 0 | (8xi)-cinchonan-9-ol; cinchona alkaloid | metabolite |
| 7-chloro-4-aminoquinoline 7-chloro-4-aminoquinoline: structure given in first source | 2.46 | 2 | 0 | aminoquinoline | |
| mmv665852 MMV665852: an antischistosomal agent | 2.46 | 2 | 0 | ||
| 1,3,4,10-Tetrahydro-9(2H)-acridinone [no description available] | 2.46 | 2 | 0 | acridines | |
| wr 158122 WR 158122: structure | 2.46 | 2 | 0 | ||
| 10-deazaaminopterin [no description available] | 2.06 | 1 | 0 | ||
| dihydroergocristine Dihydroergocristine: A 9,10alpha-dihydro derivative of ERGOTAMINE that contains an isopropyl sidechain at the 2' position of the molecule.. dihydroergocristine : Ergocristine in which a single bond replaces the double bond between positions 9 and 10. It is used as the mesylate salt for the symptomatic treatment of mental deterioration associated with cerebrovascular insufficiency and in peripheral vascular disease. | 2.46 | 2 | 0 | ergot alkaloid | adrenergic antagonist; vasodilator agent |
| benzamil [no description available] | 2.06 | 1 | 0 | guanidines; pyrazines | |
| 3',4'-dichlorobenzamil 3',4'-dichlorobenzamil: inhibits Na-Ca exchange in membrane vesicle & papillary muscle preparations from guinea pig heart | 2.46 | 2 | 0 | guanidines; pyrazines | |
| cleistanthin b cleistanthin B: toxic constituent of Cleistanthus collinus. cleistanthin B : A member of the class of cleistanthins that is cleistanthin A in which the 3,4-di-O-methyl-D-xylopyranosyl group is replaced by a beta-D-glucopyranosyl group. | 2.46 | 2 | 0 | beta-D-glucoside; cleistanthins; monosaccharide derivative | alpha-adrenergic antagonist; antihypertensive agent; diuretic |
| n-acetyltyramine N-acetyltyramine: structure given in first source. N-acetyltyramine : A member of the class of tyramines that is tyramine in which one of the hydrogens of the amino group is replaced by an acetyl group. | 2.46 | 2 | 0 | acetamides; tyramines | animal metabolite; Aspergillus metabolite; bacterial metabolite; marine metabolite; quorum sensing inhibitor |
| 1,3-di(4-imidazolinophenoxyl)propane 1,3-di(4-imidazolinophenoxyl)propane: structure given in first source | 2.46 | 2 | 0 | ||
| 7h-pyrido(4,3-c)carbazole 7H-pyrido(4,3-c)carbazole: structure given in first source | 2.46 | 2 | 0 | ||
| imiloxan [no description available] | 2.06 | 1 | 0 | benzodioxine | |
| celastrol methyl ester celastrol methyl ester: isolated from Tripterygium wilfordii; potent inhibitory activity on both Kir2.1 and ERG1 potassium channels, leading to LONG QT SYNDROME | 2.46 | 2 | 0 | carboxylic ester | |
| epiberberine epiberberine: isolated in plants of Coptis from China | 2.06 | 1 | 0 | ||
| 2-phenyl-4-oxohydroquinoline 2-phenyl-4-oxohydroquinoline: structure given in first source | 2.46 | 2 | 0 | ||
| 3,6-bis(2-(diethylamino)ethoxy)acridine 3,6-bis(2-(diethylamino)ethoxy)acridine: structure given in first source; an analog of tilorone in which the fluorenone residue has been replaced by acridine; induces lysosomal storage of sufated glycosaminoglycans | 2.38 | 2 | 0 | ||
| cypripedin cypripedin: sensitizing agent for contact dermatitis from Lady Slipper (Cypripedium calceolus); structure | 2.46 | 2 | 0 | phenanthrol | |
| respinomycin d respinomycin D: structure given in first source; isolated from Streptomyces xanthocidicus | 2.46 | 2 | 0 | ||
| azacrin azacrin: structure | 2.04 | 1 | 0 | ||
| acetoxycycloheximide acetoxycycloheximide: structure | 2.46 | 2 | 0 | ||
| (R)-Roemerine [no description available] | 2.46 | 2 | 0 | isoquinoline alkaloid | |
| anisomycin Anisomycin: An antibiotic isolated from various Streptomyces species. It interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system.. (-)-anisomycin : An antibiotic isolated from various Streptomyces species. It interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system. | 2.04 | 1 | 0 | monohydroxypyrrolidine; organonitrogen heterocyclic antibiotic | anticoronaviral agent; antimicrobial agent; antineoplastic agent; antiparasitic agent; bacterial metabolite; DNA synthesis inhibitor; protein synthesis inhibitor |
| 2-guanidine-4-methylquinazoline 2-guanidine-4-methylquinazoline: structure given in first source | 2.46 | 2 | 0 | ||
| jatrorrhizine chloride [no description available] | 2.04 | 1 | 0 | ||
| mensacarcin mensacarcin: structure in first source | 2.06 | 1 | 0 | ||
| puromycin [no description available] | 2.46 | 2 | 0 | puromycins | antiinfective agent; antimicrobial agent; antineoplastic agent; EC 3.4.11.14 (cytosol alanyl aminopeptidase) inhibitor; EC 3.4.14.2 (dipeptidyl-peptidase II) inhibitor; nucleoside antibiotic; protein synthesis inhibitor |
| quinidine Quinidine: An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.. quinidine : A cinchona alkaloid consisting of cinchonine with the hydrogen at the 6-position of the quinoline ring substituted by methoxy. | 2.46 | 2 | 0 | cinchona alkaloid | alpha-adrenergic antagonist; anti-arrhythmia drug; antimalarial; drug allergen; EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor; EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; muscarinic antagonist; P450 inhibitor; potassium channel blocker; sodium channel blocker |
| cephaelin cephaelin: do not confuse with cephalin of brain; after emetine this is the most important alkaloid of ipecac; protein synthesis inhibitor. cephaeline : A pyridoisoquinoline comprising emetam having a hydroxy group at the 6'-position and methoxy substituents at the 7'-, 10- and 11-positions. | 2.06 | 1 | 0 | pyridoisoquinoline | |
| trichostatin a trichostatin A: chelates zinc ion in the active site of histone deacetylases, resulting in preventing histone unpacking so DNA is less available for transcription; do not confuse with TRICHOSANTHIN which is a protein; found in STREPTOMYCES | 2.04 | 1 | 0 | antibiotic antifungal agent; hydroxamic acid; trichostatin | bacterial metabolite; EC 3.5.1.98 (histone deacetylase) inhibitor; geroprotector |
| epothilone b [no description available] | 2.46 | 2 | 0 | epothilone; epoxide | antineoplastic agent; apoptosis inducer; microtubule-stabilising agent |
| wr-142,490 (+)-(11R,2'S)-erythro-mefloquine : An optically active form of [2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol having (+)-(11R,2'S)-erythro-configuration. An antimalarial agent, used in racemic form, which acts as a blood schizonticide; its mechanism of action is unknown. | 2.06 | 1 | 0 | [2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol | antimalarial |
| dactinomycin Dactinomycin: A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015) | 2.46 | 2 | 0 | actinomycin | mutagen |
| 1,3,6-trimethylpyrimido[5,4-e][1,2,4]triazine-5,7-dione [no description available] | 2.46 | 2 | 0 | pyrimidotriazine | |
| jp-1302 [no description available] | 2.46 | 2 | 0 | ||
| 7-hydroxy-2-methoxy-1,4-phenanthrenedione 7-hydroxy-2-methoxy-1,4-phenanthrenedione: structure in first source; from Dendrobium densiflorum | 2.46 | 2 | 0 | ||
| cgp 60474 [no description available] | 2.46 | 2 | 0 | substituted aniline | |
| (1S,2R)-2-(octylamino)-1-[4-(propan-2-ylthio)phenyl]-1-propanol [no description available] | 2.06 | 1 | 0 | alkylbenzene | |
| 2-[2-hydroxy-6,7-dimethoxy-4-(4-morpholinyl)-1-naphthalenyl]-N-phenylacetamide [no description available] | 2.46 | 2 | 0 | naphthols | |
| N4-(3-chlorophenyl)-6-methyl-N2-(phenylmethyl)pyrimidine-2,4-diamine [no description available] | 2.46 | 2 | 0 | aralkylamine | |
| n-(4-methylpyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine N-(4-methylpyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine: calcium-activated small conductance potassium channels inhibitor; structure in first source | 2.06 | 1 | 0 | ||
| 2,6-bis(benzimidazol-2-yl)pyridine 2,6-bis(benzimidazol-2-yl)pyridine: structure in first source | 2.46 | 2 | 0 | benzimidazoles | |
| n-(pyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine N-(pyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine: an SK channel inhibitor | 2.46 | 2 | 0 | ||
| N-[4-(1-azepanyl)phenyl]-2-chloroacetamide [no description available] | 2.46 | 2 | 0 | anilide | |
| N-(4-methylphenyl)carbamic acid (cyclopentylideneamino) ester [no description available] | 2.46 | 2 | 0 | toluenes | |
| (2'-(4-aminophenyl)-(2,5'-bi-1h-benzimidazol)-5-amine) [no description available] | 2.46 | 2 | 0 | benzimidazoles | |
| 1,4,8-trimethyl-12-quinolino[2,3-b]quinolinamine [no description available] | 2.46 | 2 | 0 | aminoquinoline | |
| 2-furanyl-(4,4,8-trimethyl-1-sulfanylidene-5-dithiolo[3,4-c]quinolinyl)methanone [no description available] | 2.46 | 2 | 0 | aromatic amide; heteroarene | |
| 1-(6-methoxy-2,2,4-trimethyl-1-quinolinyl)-2-[[5-(4-methylphenyl)-1,3,4-oxadiazol-2-yl]thio]ethanone [no description available] | 2.46 | 2 | 0 | quinolines | |
| stk295900 [no description available] | 2.46 | 2 | 0 | ||
| 6-(4-methyl-1-piperazinyl)-2-(3,4,5-trimethoxyphenyl)-1H-benzimidazole [no description available] | 2.46 | 2 | 0 | benzimidazoles | |
| N9-(4-butoxyphenyl)-6,8,10-triazaspiro[4.5]deca-6,9-diene-7,9-diamine [no description available] | 2.46 | 2 | 0 | aromatic ether | |
| N-[2-[5-(1,3-benzothiazol-2-yl)-3-ethyl-1-phenyl-2-benzimidazol-3-iumyl]ethenyl]-N-methylaniline [no description available] | 2.46 | 2 | 0 | benzimidazoles | |
| 4-(1-adamantyl)-2-methyl-1,3-thiazole [no description available] | 2.46 | 2 | 0 | thiazoles | |
| 2-amino-6-[4-(6-chloro-2-pyridinyl)-1-piperazinyl]pyridine-3,5-dicarbonitrile [no description available] | 2.46 | 2 | 0 | piperazines; pyridines | |
| 1-(4-fluorophenyl)-3-[4-(4-fluorophenyl)-2-methyl-5-(trifluoromethyl)-3-pyrazolyl]urea [no description available] | 2.46 | 2 | 0 | pyrazoles; ring assembly | |
| 2-(4,6,7-Trimethyl-2-quinazolinyl)guanidine [no description available] | 2.46 | 2 | 0 | quinazolines | |
| polysulfide rubber [no description available] | 2.46 | 2 | 0 | ||
| lch-7749944 LCH-7749944: potent p21-activated kinase 4 inhibitor, structure in first source | 2.06 | 1 | 0 | ||
| 4-(4-nitrophenyl)-N-prop-2-enyl-1-piperazinecarbothioamide [no description available] | 2.46 | 2 | 0 | piperazines | |
| zd 6474 CH 331: structure in first source | 2.46 | 2 | 0 | aromatic ether; organobromine compound; organofluorine compound; piperidines; quinazolines; secondary amine | antineoplastic agent; tyrosine kinase inhibitor |
| 5-bromo-1-(1-oxopropyl)-N,N-dipropyl-2,3-dihydroindole-7-sulfonamide [no description available] | 2.46 | 2 | 0 | indoles | |
| N-cyclohexyl-5,6,7,8-tetrahydro-4H-cyclohepta[d]isoxazole-3-carboxamide [no description available] | 2.46 | 2 | 0 | aromatic amide; heteroarene | |
| 2-[(3-ethyl-7-methyl-4-oxo-6,8-dihydro-5H-pyrido[2,3]thieno[2,4-b]pyrimidin-2-yl)thio]-N-(2-phenylethyl)acetamide [no description available] | 2.46 | 2 | 0 | organic heterobicyclic compound; organonitrogen heterocyclic compound; organosulfur heterocyclic compound | |
| trichomonacid trichomonacid: RN given refers to phosphate (1:3) salt | 2.46 | 2 | 0 | ||
| N-(4-bromo-3-methylphenyl)-2,5-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine [no description available] | 2.46 | 2 | 0 | triazolopyrimidines | |
| N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-(2-methoxyethyl)-3-oxo-1H-isoindole-4-carboxamide [no description available] | 2.46 | 2 | 0 | isoindoles | |
| cgp 71683 a [no description available] | 2.06 | 1 | 0 | naphthalenes; sulfonic acid derivative | |
| 2-(dimethylaminostyryl)-1-ethylpyridinium 2-(dimethylaminostyryl)-1-ethylpyridinium: fluorescent monitor for energetic state of isolated brown- adipose-tissue mitochondria; RN given refers to parent cpd; synonym DASPEI refers to iodide | 2.06 | 1 | 0 | pyridinium ion | |
| penicillin v [no description available] | 2.04 | 1 | 0 | 1,1'-diethyl-2,2'-cyanine; quinolines | |
| hydrocortisone acetate, (11beta)-isomer [no description available] | 2.46 | 2 | 0 | ||
| xib 4035 XIB 4035: a GFRalpha-1 agonist; structure in first source | 2.46 | 2 | 0 | ||
| 10-hydroxy-3-methyl-8-pentyl-2,4-dihydro-1H-[1]benzopyrano[3,4-c]pyridin-5-one [no description available] | 2.46 | 2 | 0 | pyridochromene | |
| lumefantrine Lumefantrine: A fluorene derivative that is used in combination with ARTEMETHER for the treatment of MALARIA (see ARTEMETHER-LUMEFANTRINE DRUG COMBINATION).. lumefantrine : A member of the class of fluorenes that is 9-(p-chlorobenzylidene)-9H-fluorene which is substitutec by chlorine at positions 2 and 7, and by a 2-(dibutylamino)-1-hydroxyethyl group at position 4. An antimalarial drug used in combination with artemether for the treatment of multi-drug resistant strains of falciparum malaria. | 2.46 | 2 | 0 | fluorenes; monochlorobenzenes; secondary alcohol; tertiary amine | antimalarial |
| asialo gm1 ganglioside [no description available] | 2.37 | 2 | 0 | ||
| suloctidil Suloctidil: A peripheral vasodilator that was formerly used in the management of peripheral and cerebral vascular disorders. It is hepatotoxic and fatalities have occurred. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1312) | 2.04 | 1 | 0 | ||
| edatrexate edatrexate: structure given in first source | 2.46 | 2 | 0 | glutamic acid derivative | |
| cgp 71683 a CGP 71683 A: selective NPY Y(5) receptor antagonist; structure in first source | 2.04 | 1 | 0 | ||
| norketotifen norketotifen: Ketotifen is an antimalarial prodrug of norketotifen with blood schizonticidal and liver-stage efficacy; structure in first source | 2.06 | 1 | 0 | organosulfur heterocyclic compound | |
| g(m1) ganglioside G(M1) Ganglioside: A specific monosialoganglioside that accumulates abnormally within the nervous system due to a deficiency of GM1-b-galactosidase, resulting in GM1 gangliosidosis.. ganglioside GM1 : A sialotetraosylceramide consisting of a branched pentasaccharide made up from one sialyl residue, two galactose residues, one N-acetylgalactosamine residue and a glucose residue at the reducing end attached to N-stearoylsphingosine via a beta-linkage. | 2.67 | 3 | 0 | alpha-N-acetylneuraminosyl-(2->3)-[beta-D-galactosyl-(1->3)-N-acetyl-beta-D-galactosaminyl-(1->4)]-beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1')-N-acylsphingosine; sialotetraosylceramide | |
| artenimol artenimol: derivative of antimalarial drug artemisinin (quinghaosu) | 2.04 | 1 | 0 | ||
| aee 788 AEE 788: structure in first source | 2.46 | 2 | 0 | 6-{4-[(4-ethylpiperazin-1-yl)methyl]phenyl}-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine | angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; epidermal growth factor receptor antagonist; trypanocidal drug |
| tomaymycin tomaymycin: structure. tomaymycin : A pyrrolobenzodiazepine that is (11aS)-2,3,5,10,11,11a-hexahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepine which is substituted at positions 2,5,7,8 and 11R by ethylidene, oxo, methoxy, hydroxy and methoxy groups, respectively. It is a natural product of Streptomyces achromogenes that binds covalently with guanine in the minor groove of DNA. It is an antitumoral compound which is active in ovarian, plasmacytoma, and leukemia cancer cell lines at nanomolar concentrations.. (Z)-tomaymycin : The (Z)-isomer of tomaymycin. | 2.46 | 2 | 0 | tomaymycin | |
| amodiaquine hydrochloride [no description available] | 2.04 | 1 | 0 | ||
| gramicidin a Gramicidin: A group of peptide antibiotics from BACILLUS brevis. Gramicidin C or S is a cyclic, ten-amino acid polypeptide and gramicidins A, B, D are linear. Gramicidin is one of the two principal components of TYROTHRICIN. | 2.46 | 2 | 0 | ||
| N-methyl-3-[5-(3-phenylpropyl)-1,3,4-oxadiazol-2-yl]-N-(3-thiophenylmethyl)propanamide [no description available] | 2.46 | 2 | 0 | benzenes | |
| rs 39604 RS 39604 hydrochloride : A hydrochloride salt obtained by mixing equimolar amounts of RS 39604 with hydrochloric acid. A potent and selective 5-HT4 antagonist, with a pKi of 9.1 at 5-HT4 receptors in guinea pig striatal membranes and greater than 1000-fold selectivity over 5-HT1A, 2C, 3 and D1, D2, M1, M2, AT1, B1 and alpha1C receptors. The ketone group gives RS 39604 a relatively long half life; it is also orally active and so suitable for in vivo studies.. RS 39604 : An aromatic ether that is the 3,5-dimethoxybenzyl derivative of N-(2-{4-[3-(4-amino-5-chloro-2-hydroxyphenyl)-3-oxopropyl]piperidin-1-yl}ethyl)methanesulfonamide. A potent and selective 5-HT4 antagonist, with a pKi of 9.1 at 5-HT4 receptors in guinea pig striatal membranes and greater than 1000-fold selectivity over 5-HT1A, 2C, 3 and D1, D2, M1, M2, AT1, B1 and alpha1C receptors. The ketone group gives RS 39604 a relatively long half life; it is also orally active and so suitable for in vivo studies. | 2.04 | 1 | 0 | hydrochloride | serotonergic antagonist |
| orabase Orabase: used in therapy of oral mucosal ulcers | 1.98 | 1 | 0 | ||
| guanosine ribonucleoside : Any nucleoside where the sugar component is D-ribose. | 1.99 | 1 | 0 | guanosines; purines D-ribonucleoside | fundamental metabolite |
| 1-[amino-[(6-methoxy-4-methyl-2-quinazolinyl)amino]methylidene]-3-phenylurea [no description available] | 2.46 | 2 | 0 | quinazolines | |
| isatoribine anhydrous [no description available] | 1.99 | 1 | 0 |
| Condition | Indicated | Relationship Strength | Studies | Trials |
|---|---|---|---|---|
| Infections, Plasmodium [description not available] | 0 | 2.46 | 2 | 0 |
| Malaria A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia. | 0 | 2.46 | 2 | 0 |
| Cytomegalic Inclusion Disease [description not available] | 0 | 1.98 | 1 | 0 |
| Herpes Simplex Virus Infection [description not available] | 0 | 1.98 | 1 | 0 |
| B Virus Infection [description not available] | 0 | 1.98 | 1 | 0 |
| Cytomegalovirus Infections Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults. | 0 | 1.98 | 1 | 0 |
| Herpes Simplex A group of acute infections caused by herpes simplex virus type 1 or type 2 that is characterized by the development of one or more small fluid-filled vesicles with a raised erythematous base on the skin or mucous membrane. It occurs as a primary infection or recurs due to a reactivation of a latent infection. (Dorland, 27th ed.) | 0 | 1.98 | 1 | 0 |
| Lysosomal Enzyme Disorders [description not available] | 0 | 1.98 | 1 | 0 |
| Acquired Immune Deficiency Syndrome [description not available] | 0 | 1.99 | 1 | 0 |
| Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. | 0 | 2.38 | 2 | 0 |
| Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. | 0 | 1.99 | 1 | 0 |
| Mucopolysaccharidosis [description not available] | 0 | 2.38 | 2 | 0 |
| Mucopolysaccharidoses Group of lysosomal storage diseases each caused by an inherited deficiency of an enzyme involved in the degradation of glycosaminoglycans (mucopolysaccharides). The diseases are progressive and often display a wide spectrum of clinical severity within one enzyme deficiency. | 0 | 2.38 | 2 | 0 |
| Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time. | 0 | 1.97 | 1 | 0 |
| Brain Inflammation [description not available] | 0 | 1.97 | 1 | 0 |
| Infections, Togaviridae [description not available] | 0 | 1.97 | 1 | 0 |
| Encephalitis Inflammation of the BRAIN due to infection, autoimmune processes, toxins, and other conditions. Viral infections (see ENCEPHALITIS, VIRAL) are a relatively frequent cause of this condition. | 0 | 1.97 | 1 | 0 |
| Arenaviridae Infections Virus diseases caused by the ARENAVIRIDAE. | 0 | 1.97 | 1 | 0 |
| Adenocarcinoma, Basal Cell [description not available] | 0 | 1.97 | 1 | 0 |
| Colorectal Cancer [description not available] | 0 | 1.97 | 1 | 0 |
| Adenocarcinoma A malignant epithelial tumor with a glandular organization. | 0 | 1.97 | 1 | 0 |
| Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI. | 0 | 1.97 | 1 | 0 |
| American Trypanosomiasis [description not available] | 0 | 1.97 | 1 | 0 |
| Chagas Disease Infection with the protozoan parasite TRYPANOSOMA CRUZI, a form of TRYPANOSOMIASIS endemic in Central and South America. It is named after the Brazilian physician Carlos Chagas, who discovered the parasite. Infection by the parasite (positive serologic result only) is distinguished from the clinical manifestations that develop years later, such as destruction of PARASYMPATHETIC GANGLIA; CHAGAS CARDIOMYOPATHY; and dysfunction of the ESOPHAGUS or COLON. | 0 | 1.97 | 1 | 0 |
| Germinoblastoma [description not available] | 0 | 1.96 | 1 | 0 |
| Lymphoma A general term for various neoplastic diseases of the lymphoid tissue. | 0 | 1.96 | 1 | 0 |
| Experimental Leukemia [description not available] | 0 | 1.96 | 1 | 0 |